Clinical trials: Multiple Sclerosis Subjects
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Multiple Sclerosis
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
The primary objective of the study is to assess the effect of long-term treatment with prolonged-release fampridine (BIIB041) 10 mg twice daily on the physical component scale (PCS) of the Short Form 36 Health Status…
- Trial name
- ENABLE (NCT01480076)
- Testing
- Fampridine
- Where
- 59 sites in Australia, Belgium and 7 more
- Volunteers
- 901 people
- Sponsor
- Biogen
Spasticity, Multiple Sclerosis
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study is to evaluate the maintenance of effect after long-term treatment with Sativex® in subjects with symptoms of spasticity due to Multiple Sclerosis (MS) who have been receiving long-term benefit from…
- Trial name
- NCT00702468
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of the study is to further evaluate the long-term safety and tolerability profiles of BG00002 (natalizumab) in Japanese participants with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01416155
- Testing
- natalizumab
- Where
- 22 sites in Japan
- Volunteers
- 97 people
- Sponsor
- Biogen